RW-93
Pharmaceutical compound
RW-93 is a drug which acts as a potent and selective sirtuin 2 (SIRT2) inhibitor. It inhibits SIRT2 with an IC50 of 15.5 nM, and is highly selective over SIRT1, SIRT3 and SIRT5, however its activity has not been reported at SIRT4, SIRT6 or SIRT7. It represents a further development of FM358, which resulted from a lead-structure-based hybridization concept derived from SirReal2 and 24a. It was developed to assist with research into the role of SIRT2 in degenerative diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis.
Sources and credits
This article is adapted from the Wikipedia article “RW-93”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- RW-93 structure.png by Meodipt (talk), Public domain
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.